Healthcare ❯ Regulatory Affairs ❯ FDA Approvals

Drug Development

Clinical Trials Pompe Disease Cutaneous T-cell Lymphoma Tolebrutinib TECVAYLI Prader-Willi Syndrome

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

The all-cash deal gives the Italian group a U.S. foothold to scale a Brain Health–focused rare-disease platform.

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

BioMarin to Acquire Amicus for $4.8 Billion in Cash